RT Journal Article
SR Electronic
T1 Risk factors for severe PCR-positive SARS-CoV-2 infection in hospitalized children: a multicenter cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.28.21265616
DO 10.1101/2021.10.28.21265616
A1 Schober, Tilmann
A1 Caya, Chelsea
A1 Barton, Michelle
A1 Bayliss, Ann
A1 Bitnun, Ari
A1 Bowes, Jennifer
A1 Brenes-Chacon, Helena
A1 Bullard, Jared
A1 Cooke, Suzette
A1 Dewan, Tammie
A1 Dwilow, Rachel
A1 Tal, Tala El
A1 Foo, Cheryl
A1 Gill, Peter
A1 Aski, Behzad Haghighi
A1 Kakkar, Fatima
A1 Lautermilch, Janell
A1 Laxer, Ronald M.
A1 Lefebvre, Marie-Astrid
A1 Leifso, Kirk
A1 Saux, Nicole Le
A1 Lopez, Alison
A1 Manafi, Ali
A1 Morris, Shaun K.
A1 Nateghian, Alireza
A1 Panetta, Luc
A1 Petel, Dara
A1 Piché, Dominique
A1 Purewal, Rupeena
A1 Restivo, Lea
A1 Roberts, Ashley
A1 Sadarangani, Manish
A1 Scuccimarri, Rosie
A1 Soriano-Fallas, Alejandra
A1 Tehseen, Sarah
A1 Top, Karina A.
A1 Ulloa-Gutierrez, Rolando
A1 Viel-Thériault, Isabelle
A1 Wong, Jacqueline K.
A1 Yea, Carmen
A1 Yeh, Ann
A1 Yock-Corrales, Adriana
A1 Robinson, Joan
A1 Papenburg, Jesse
YR 2021
UL http://medrxiv.org/content/early/2021/11/08/2021.10.28.21265616.abstract
AB Importance Children are less likely than adults to have severe outcomes from SARS-CoV-2 infection and the corresponding risk factors are not well established.Objective To identify risk factors for severe disease in symptomatic children hospitalized for PCR-positive SARS-CoV-2 infection.Design Cohort study, enrollment from February 1, 2020 until May 31, 2021Setting 15 children’s hospitals in Canada, Iran, and Costa RicaParticipants Patients <18 years of age hospitalized with symptomatic SARS-CoV-2 infection, including PCR-positive multisystem inflammatory syndrome in children (MIS-C)Exposures Variables assessed for their association with disease severity included patient demographics, presence of comorbidities, clinical manifestations, laboratory parameters and chest imaging findings.Main Outcomes and Measures The primary outcome was severe disease defined as a WHO COVID-19 clinical progression scale of ≥6, i.e., requirement of non-invasive ventilation, high flow nasal cannula, mechanical ventilation, vasopressors, or death. Multivariable logistic regression was used to evaluate factors associated with severe disease.Results We identified 403 hospitalizations. Median age was 3.78 years (IQR 0.53-10.77). At least one comorbidity was present in 46.4% (187/403) and multiple comorbidities in 18.6% (75/403). Severe disease occurred in 33.8% (102/403). In multivariable analyses, presence of multiple comorbidities (adjusted odds ratio 2.24, 95% confidence interval 1.04-4.81), obesity (2.87, 1.19-6.93), neurological disorder (3.22, 1.37-7.56), anemia, and/or hemoglobinopathy (5.88, 1.30-26.46), shortness of breath (4.37, 2.08-9.16), bacterial and/or viral coinfections (2.26, 1.08-4.73), chest imaging compatible with COVID-19 (2.99, 1.51-5.92), neutrophilia (2.60, 1.35-5.02), and MIS-C diagnosis (3.86, 1.56-9.51) were independent risk factors for severity. Comorbidities, especially obesity (40.9% vs 3.9%, p<0.001), were more frequently present in adolescents ≥12 years of age. Neurological disorder (3.16, 1.19-8.43) in children <12 years of age and obesity (3.21, 1.15-8.93) in adolescents were the specific comorbidities associated with disease severity in age-stratified adjusted analyses. Sensitivity analyses excluding the 81 cases with MIS-C did not substantially change the identified risk factors.Conclusions and Relevance Pediatric risk factors for severe SARS-CoV-2 infection vary according to age and can potentially guide vaccination programs and treatment approaches in children.Question What are the risk factors for severe disease in children hospitalized for PCR-positive SARS-CoV-2 infection?Findings In this multinational cohort study of 403 children, multiple comorbidities, obesity, neurological disorder, anemia, and/or hemoglobinopathy, shortness of breath, bacterial and/or viral coinfections, chest imaging compatible with COVID-19, neutrophilia, and MIS-C diagnosis were independent risk factors for severity. The risk profile and presence of comorbidities differed between pediatric age groups, but age itself was not associated with severe outcomes.Meaning These results can inform targeted treatment approaches and vaccine programs that focus on patient groups with the highest risk of severe outcomes.Competing Interest StatementManish Sadarangani has been an investigator on projects funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. Jesse Papenburg reports grants to his institution from MedImmune, Sanofi Pasteur and AbbVie, and personal fees from AbbVie, all outside of the submitted work. Shaun K Morris has received honoraria for lectures from GlaxoSmithKline and was a member of an ad hoc advisory board for Pfizer Canada, both outside of the submitted work.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The following Ethics committees/IRBs all gave approval for this work: Comite Etico Cientifico Hospital Nacional de Ninos, Costa Rica; Iran University of Medical Sciences Ethics Review Committee, Iran; The Hospital for Sick Children Research Ethics Board, Canada; Pediatric Panel of the Research Ethics Board of the Research Institute of the McGill University Health Centre, Canada; Conjoint Health Research Ethics Board, University of Calgary, Canada; Children's Hospital of Eastern Ontario Research Ethics Board, Canada; University of British Columbia Children's and Women's Research Ethics Board, Canada; Health Research Ethics Board, University of Manitoba, Canada; University of Saskatchewan Biomedical Research Ethics Board, Canada; Hamilton Integrated Research Ethics Board, Canada; Centre Hospitalier Universitaire de Quebec-Universite Laval, Canada;,Health Research Ethics Board, University of Alberta, Canada; CHU Sainte-Justine, Universite de Montreal, Canada; Lawson Health Research Institute, Canada; Trillium Health Partners Research Ethics Board, Canada; Queen's University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board, Canada; IWK Research Ethics Board, CanadaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding authors will consider data sharing requests that are accompanied by a study protocol and approval by an independent research ethics board.